1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr B McNamara
|
|
b)
|
Position/status
|
CEO, GSK Consumer Healthcare
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in ADSs following the re-investment
of dividends paid to shareholders on 13 July 2017 on ADSs held in
the Company's 2009 Performance Share Plan.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
$42.50
|
388.248
|
||
$42.50
|
77.675
|
||
$42.50
|
599.205
|
||
d)
|
Aggregated
information
Aggregated
volume Price
|
1,065.128
$42.50
|
|
e)
|
Date of the
transaction
|
2017-07-14
|
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr D E Troy
|
|
b)
|
Position/status
|
SVP & General Counsel
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in ADSs following the re-investment
of dividends paid to shareholders on 13 July 2017 on ADSs held in
the Company's 2009 Performance Share Plan.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
$42.50
|
1,057.882
|
||
$42.50
|
1,227.338
|
||
d)
|
Aggregated
information
Aggregated
volume Price
|
2,285.22
$42.50
|
|
e)
|
Date of the
transaction
|
2017-07-14
|
|
f)
|
Place
of the transaction
|
n/a
|
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: July
17, 2017
|
|
|
|
|
By: VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|